About RevBio
RevBio is a Healthcare company based in Lowell (United States) founded in 2014 by Michael Brown, Brian Hess, Jonathan Slotkin, George Kay, and Grayson Allen. Synthetic adhesives for bone and dental repair are developed. It operates in the Healthcare and Chemicals & Materials sectors. RevBio has raised $24.42 million across 16 funding rounds from investors including NIH, Pacific Dental Services and HHS. Its chief executive, as recorded, is Brian Hess. RevBio offers products and services including TETRANITE. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is RevBio Inc. Its competitors include SINTX, MiMedx Group and Theradaptive; 2 of its 3 listed competitors have raised funding.
Company details
RevBio was founded in 2014 in Lowell, United States, within the biotechnology sector. Synthetic adhesives for bone and dental repair are developed using proprietary Tetranite technology, a bio-engineered protein derived from worms. Applications include implant stabilization, fracture repair, spine fusion, dental bone grafting, joint reconstruction, and cranial flap fixation, with operations centered on advancing these medical solutions.
- Headquarters Lowell, United States
- Founders Michael Brown, Brian Hess, Jonathan Slotkin, George Kay, Grayson Allen
- SectorsHealthcareChemicals & Materials
- Website revbio.com
- Social LinkedIn X Instagram
- Legal Name Revbio Inc
- Total Equity Funding$24.42M (USD)
in 16 rounds
- Latest Funding Round$1.7M (USD), Grant
Sep 2024
- InvestorsNIH
& 4 more
Products & Services of RevBio
RevBio offers a comprehensive portfolio of products and services, including TETRANITE.
Synthetic adhesive for bone repair and fixation in medical procedures.
Funding Insights of RevBio
RevBio has successfully raised a total of $24.42M across 16 strategic funding rounds. The most recent funding activity was a Grant round of $1.7 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.42M
- Total Rounds 16
- Last Round Grant — $1.7M
- First Round $50,000
(Oct 2015)
- Investors Count 5
Latest 10 of 16 funding rounds of RevBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $1.7M | Grant | – | – | |
| Oct 2023 | Grant | – | – | ||
| Sep 2023 | $2.99M | Grant | – | – | |
| Jun 2023 | $2.65M | Debt – Conventional | – | – | – |
| Jun 2023 | $2M | Grant | – | – | |
| Apr 2023 | $6.91M | Series A | – | – | – |
| Feb 2023 | Series A | – | Pacific Dental Services | – | |
| Aug 2022 | $375,000 | Grant | – | – | |
| May 2022 | $9.01M | Series A | – | – | – |
| Jun 2020 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in RevBio
RevBio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Pacific Dental Services and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage entrepreneurs are accelerated through MassChallenge's program. | masschallenge.org | Boston, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Support provider for dental services | 1994 | pacificdentalservices.com | Los Angeles, United States | |
Degrees across diversified streams are offered by the university. | 1787 | pitt.edu | United States |
Investor details for RevBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RevBio
27 people are tracked at RevBio (8 in leadership, 18 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Michael Brown | Co-Founder | Leadership |
Brian Hess | Co-Founder & CEO | Leadership |
Jonathan Slotkin | Co-Founder | Leadership |
George Kay | Co-Founder & Chief Scientific Officer | Leadership |
Grayson Allen | Co-Founder & CFO & COO | Leadership |
D. Grayson Allen | COO & CFO | Leadership |
Kevin Foley | Chief Medical Officer | Leadership |
Michael Tiedemann, BFA, MBA | Chief Marketing Officer | Leadership |
Paul A. Fugazzotto | Dental Advisor | Board & advisors |
Alan S. Pollack | Sr. Dir. Dental Clinical Operations | Board & advisors |
Alvaro Gracia | Dental Advisor | Board & advisors |
Eric Woodard | Orthopaedic Advisor | Board & advisors |
Michael J. Weaver | Orthopaedic Advisor | Board & advisors |
Art Coury | Orthopaedic Advisor | Board & advisors |
Gino DeSimone | Business Advisor | Board & advisors |
Rick Gennett | Business Advisor | Board & advisors |
Michael A. Pikos | Dental Advisor | Board & advisors |
Michael R. Norton | Dental Advisor | Board & advisors |
R. Bruce Donoff | Dental Advisor | Board & advisors |
John Lazor | Orthopaedic Advisor | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for RevBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of RevBio
3 dated milestones of RevBio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded RevBio is founded.
- Funding First funding round of $50K.
- Funding Latest funding round, Grant, of $1.7M.
Competitors of RevBio
RevBio has 3 listed competitors in our database, 2 of them funded. They include SINTX, MiMedx Group and Theradaptive.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sintx.com | 1996 | Salt Lake, United States | $22.13M | 41 | Silicon nitride medical devices are manufactured for interbody fusion. | |
| mimedx.com | 1985 | Marietta, United States | 735 | Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | ||
| theradaptive.com | 2004 | Boston, United States | $32.2M | 21 | Therapeutic delivery platform is developed for orthopedic clinical indications. |
Detailed competitors of RevBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RevBio
The website of RevBio (revbio.com) receives about 3.1K visits a month.
- Monthly visits3.1K
▲ 41.8% vs previous month
Websites whose visitors overlap most with RevBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| accelusinc.com | 100% | 1.9K | #8,982,071 | View details | |
| truedigitalsurgery.com | 94% | 2.8K | #5,794,715 | View details | |
semmes-murphey.com | semmes-murphey.com | 72% | #2,191,041 | – |
Top companies in Orthopedics
3 companies that operate in the same segment as RevBio (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Revbio
Complete news archive for RevBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RevBio
RevBio was founded in 2014 and raised its 1st funding round 1 year after it was founded.
RevBio is headquartered in Lowell, United States. It is registered at Lowell, Massachusetts, United States.
Brian Hess is the CEO of RevBio, as recorded in our data. They have also founded this company.
RevBio is a funded company, having raised a total of $24.42M across 16 funding rounds to date.
RevBio was founded in 2014 in Lowell, United States, within the biotechnology sector. Synthetic adhesives for bone and dental repair are developed using proprietary Tetranite technology, a bio-engineered protein derived from worms. Applications include implant stabilization, fracture repair, spine fusion, dental bone grafting, joint reconstruction, and cranial flap fixation, with operations centered on advancing these medical solutions.
RevBio's top competitors include Theradaptive, MiMedx Group and SINTX.
RevBio offers TETRANITE.
RevBio has 5 investors. Key investors include NIH, Pacific Dental Services, HHS, University of Pittsburgh, and MassChallenge.
RevBio operates through Revbio Inc.